Oct 22, 2018 - Names on the move ahead of the open.
Oct 20, 2018 - The FDA approves Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi's (NYSE:SNY) DUPIXENT (dupilumab) as add-on maintenance therapy in patients with moderate-to-severe asthma aged
Oct 16, 2018 - October's top net gain safer Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.WallStars all s
Oct 15, 2018 - Aimmune Therapeutics (AIMT +1.3%) is up on light volume on the heels of the initiation of a Phase 2 clinical trial evaluating AR101 with adjunctive DUPIXENT (dupilumab) in peanut-allergy patients.The
Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
Oct 15, 2018 - The Boston Globe reports that Sanofi's (NYSE:SNY) U.S. unit is planning a major expansion in East Cambridge, MA that may be as large as 400K square feet, enough to house 2K employees. The former rail
Oct 11, 2018 - Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Oct 09, 2018 - Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended for the prevention and treatment of several illnesses.The market is too pessimist
Oct 05, 2018 - Data from Phase III trials of Lilly/Boehringer's Jardiance in Type 1 diabetes supports submission and commercialization, bringing another competitor into the market.Lexicon's sotagliflozin is not out
Oct 03, 2018 - The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.